胡子奇, 廖雁君, 刘玉民, 李淑坤, 仝萌, 汪晶, 舒娈. 葛根素对高脂诱导糖尿病小鼠抑郁症状的改善作用及机制研究J. 药学学报, 2021,56(5): 1391-1399. doi: 10.16438/j.0513-4870.2020-1971
引用本文: 胡子奇, 廖雁君, 刘玉民, 李淑坤, 仝萌, 汪晶, 舒娈. 葛根素对高脂诱导糖尿病小鼠抑郁症状的改善作用及机制研究J. 药学学报, 2021,56(5): 1391-1399. doi: 10.16438/j.0513-4870.2020-1971
HU Zi-qi, LIAO Yan-jun, LIU Yu-min, LI Shu-kun, TONG Meng, WANG Jing, SHU Luan. Puerarin ameliorates depressive symptoms in diabetic mice induced by high-fat dietJ. Acta Pharmaceutica Sinica, 2021,56(5): 1391-1399. doi: 10.16438/j.0513-4870.2020-1971
Citation: HU Zi-qi, LIAO Yan-jun, LIU Yu-min, LI Shu-kun, TONG Meng, WANG Jing, SHU Luan. Puerarin ameliorates depressive symptoms in diabetic mice induced by high-fat dietJ. Acta Pharmaceutica Sinica, 2021,56(5): 1391-1399. doi: 10.16438/j.0513-4870.2020-1971

葛根素对高脂诱导糖尿病小鼠抑郁症状的改善作用及机制研究

Puerarin ameliorates depressive symptoms in diabetic mice induced by high-fat diet

  • 摘要: 前期研究表明,中药葛根活性成分葛根素通过激活胰高血糖素样肽-1受体(glucagon-like peptide-1 receptor,GLP-1R)通路改善高脂(high-fat diet,HFD)诱导糖尿病小鼠糖代谢,本研究拟进一步评价葛根素对HFD小鼠抑郁症状的影响。采用高脂饲料长期喂养诱导小鼠产生2型糖尿病及并发抑郁样症状,动物福利和实验过程均遵循南京中医药大学附属中西医结合医院动物伦理委员会的规定(批准号:AEWC-025)。实验分为:对照组、模型组、模型/葛根素(150 mg·kg-1·day-1)组和模型/氟西汀(15 mg·kg-1·day-1)组。每日1次灌胃给药,连续给药6周后,进行小鼠口服葡萄糖耐量测试(oral glucose tolerance test,OGTT)及行为学测试分析。同时采用ELISA(enzyme-linked immunosorbent assay)法检测各组小鼠血清中白介素(interleukin,IL)-1β、IL-6、5-羟色胺(5-hydroxytryptamine,5-HT)和皮质酮(corticosterone,CORT)含量。Western blot法检测小鼠大脑海马体中神经可塑性以及抑郁症相关蛋白的激活与表达水平。同时采用小鼠海马神经元细胞系HT22细胞考察葛根素对细胞形态与生存的保护作用。结果显示葛根素能够有效保护在高糖与皮质酮环境下HT22细胞的生存。给予葛根素治疗后,糖尿病小鼠血糖调节能力改善,抑郁症状减轻,5-HT含量升高,CORT、IL-1β和IL-6含量降低。海马组织中GLP-1R/Wnt/mTOR(mammalian target of rapamycin)信号中相关蛋白上调,提示其对糖尿病小鼠抑郁症状的改善作用可能与激活GLP-1R/Wnt/mTOR信号通路相关。本研究表明,葛根素能够显著改善高脂诱导的糖尿病小鼠抑郁症状,其作用可能是通过激活GLP-1R/Wnt/mTOR信号通路,改善海马神经可塑性而实现。

     

    Abstract: Our previous studies have shown that puerarin, an active component of the traditional Chinese medicine-Pueraria Lobata, can improve glycometabolism in high-fat diet (HFD) mice with diabetes by activating the glucagon-like peptide-1 receptor (GLP-1R) pathway. This study intends to further evaluate the effect of puerarin on depressive symptoms in HFD mice. Long-term HFD induces type 2 diabetes and depressive-like symptoms in mice. Animal welfare and experimental procedures follow the regulations of the Animal Ethics Committee of the Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Traditional Chinese Medicine (approval No. AEWC-025). The experiment was divided into:control group, model group, model/puerarin (150 mg·kg-1·day-1) group, and model/fluoxetine (15 mg·kg-1·day-1) group. The oral glucose tolerance test (OGTT) and behavioral experimental analysis were performed after 6 weeks of continuous administration. Afterwards, enzyme-linked immunosorbent assay (ELISA) was used to detect interleukin-1β (IL-1β), interleukin-6 (IL-6), 5-hydroxytryptamine (5-HT), and corticosterone (CORT) in serum of mice for each group. Western blot assays were used to detect the level of activation and expression of proteins related to neuroplasticity and depressive disorder in the hippocampus. Moreover, HT-22 cell line was used to investigate the protective effect of puerarin on cell morphology and survival. The results show that puerarin can effectively maintain the survival of HT22 in an environment with high glucose and corticosterone. Meantime, the glycemic regulation of diabetic mice was improved after treatment of puerarin, the depressive symptoms were alleviated, the 5-HT increased, and the corticosterone, IL-1β, and IL-6 decreased in the serum. The up-regulation of related proteins in GLP-1R/Wnt/mTOR (mammalian target of rapamycin) signaling in hippocampus suggests that its effect on ameliorating depression in diabetic mice may be related to the activation of GLP-1R/Wnt/mTOR signaling pathway. This study shows that puerarin can significantly ameliorate the depressive symptoms of HFD induced diabetic mice which might be achieved through activating the GLP-1R/Wnt/mTOR signaling pathway and improving hippocampal neuroplasticity.

     

/

返回文章
返回